Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Completed
Novartis Pharmaceuticals
Phase 2
2006-12-01
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day)
everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite
prior treatment with targeted therapy and chemotherapy.
Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
Completed
Novartis Pharmaceuticals
Phase 3
2008-01-01
This trial was designed to address important issues that impact recipients of liver
allografts as well as clinicians, ie, renal function, reduction or discontinuation of
tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus
(HCV) positive patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
